Bank of New York Mellon Corp Purchases New Position in Becton, Dickinson and Company $BDX

Key Points

• Bank of New York Mellon acquired 1.63 million Becton, Dickinson and Company shares in the second quarter, valued at approximately $247.4 million and representing a 0.59% stake. Institutional investors collectively own 86.97% of BDX.
• BDX exceeded quarterly earnings expectations, reporting $3.23 in EPS and $4.98 billion in revenue; revenue increased 5.4% year over year. The company guided to fiscal 2026 EPS of $12.62–$12.72.
• The stock recently traded near its 52-week high at $191.95, while analysts maintained a consensus “Hold” rating with an average price target of $185.67. The company also declared a $1.05 quarterly dividend, or $4.20 annually.

Bank of New York Mellon Corp acquired a new position in Becton, Dickinson and Company (NYSE:BDX - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 1,634,649 shares of the medical instruments supplier's stock, valued at approximately $247,372,000. Bank of New York Mellon Corp owned 0.59% of Becton, Dickinson and Company at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Auto Owners Insurance Co boosted its stake in Becton, Dickinson and Company by 22,225.2% in the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier's stock worth $790,079,000 after purchasing an additional 40,528,680 shares during the period. Vanguard Group Inc. lifted its stake in Becton, Dickinson and Company by 13.0% in the 4th quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier's stock worth $7,118,282,000 after purchasing an additional 4,223,149 shares in the last quarter. State Street Corp lifted its stake in Becton, Dickinson and Company by 0.8% in the 4th quarter. State Street Corp now owns 13,989,132 shares of the medical instruments supplier's stock worth $2,714,871,000 after purchasing an additional 116,737 shares in the last quarter. First Eagle Investment Management LLC boosted its holdings in Becton, Dickinson and Company by 16.5% in the 4th quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier's stock valued at $2,260,139,000 after purchasing an additional 1,651,592 shares during the period. Finally, Geode Capital Management LLC boosted its stake in Becton, Dickinson and Company by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 6,885,361 shares of the medical instruments supplier's stock valued at $1,331,165,000 after buying an additional 53,884 shares during the period. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the company's stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares of the company's stock, valued at approximately $20,380,155. This represents a 3.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the sale, the executive vice president owned 14,856 shares of the company's stock, valued at approximately $2,686,559.04. This represents a 14.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 11,779 shares of company stock valued at $1,974,669 over the last three months. 0.40% of the stock is owned by company insiders.

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock opened at $191.95 on Friday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $192.30. The company has a fifty day moving average of $161.58 and a 200-day moving average of $161.13. The stock has a market capitalization of $52.89 billion, a price-to-earnings ratio of 57.82, a price-to-earnings-growth ratio of 13.53 and a beta of 0.19.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping analysts' consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company had revenue of $4.98 billion for the quarter, compared to analysts' expectations of $4.89 billion. During the same quarter last year, the company earned $3.68 EPS. The firm's revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities research analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be issued a $1.05 dividend. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company's dividend payout ratio (DPR) is currently 126.51%.

Analyst Upgrades and Downgrades

BDX has been the subject of several recent analyst reports. Evercore set a $180.00 target price on Becton, Dickinson and Company in a research report on Monday, July 6th. Stifel Nicolaus set a $195.00 price objective on Becton, Dickinson and Company in a report on Friday, August 7th. Barclays lifted their target price on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an "overweight" rating in a research report on Monday, May 11th. Jefferies Financial Group reissued a "buy" rating and issued a $210.00 price target on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Finally, Piper Sandler increased their price target on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a "neutral" rating in a report on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $185.67.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source